SJH_18-026

GO40241: A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (Impower030)

The purpose of this study is to compare the effects, good or bad, of atezolizumab plus chemotherapy (in this study, chemotherapy will be a combination of either nab-paclitaxel with carboplatin, or pemetrexed with carboplatin or cisplatin) versus placebo (an inactive substance that looks like atezolizumab) plus chemotherapy on patients with resectable NSCLC to find out which is better.
Phase III
NCT03456063
All Other|Cancer
Lung
Timothy Byun, M.D.
Lavinia Dobrea
  • xSJH Southern California